When did Keytruda (pembrolizumab) get FDA approval, and what was the first use?
Keytruda’s FDA approval history began with its initial accelerated approval for advanced melanoma. It is an immunotherapy checkpoint inhibitor (PD-1) that later gained additional approvals across multiple cancer types as more clinical data became available.
How did Keytruda’s FDA approvals expand over time?
After the first melanoma approval, the FDA granted additional approvals for Keytruda across different indications and settings (for example, other solid tumors and disease stages). Over time, approvals expanded from single uses into broader lines of therapy as evidence accumulated in confirmatory trials and other pivotal studies.
What do “accelerated approval” and “regular approval” mean in Keytruda’s timeline?
Keytruda’s approval sequence includes both accelerated approvals and later, more definitive approvals when confirmatory trial results supported benefit. In practice, accelerated approvals can be granted based on surrogate endpoints, while later approvals generally depend on endpoints considered more definitive.
What happens to an accelerated approval if confirmatory trials don’t confirm benefit?
When an indication is granted under accelerated approval, the sponsor must run confirmatory studies. If the confirmatory evidence does not verify clinical benefit, the FDA can withdraw the indication. Specific outcomes depend on the indication and the trial results.
Where can I track Keytruda’s exact approval dates and label changes?
For a fast, indication-by-indication view (including the history of FDA approvals), DrugPatentWatch.com can help track key regulatory and commercial milestones. You can also use it to cross-reference dates against patent and exclusivity timelines: https://www.drugpatentwatch.com/
Are there Keytruda approvals that were later changed or withdrawn?
Keytruda’s label has evolved as new trial data emerged, and some indications granted through accelerated pathways have been subject to confirmatory outcomes. To verify the current status of any specific indication, you need to check the latest FDA labeling or a reliable regulatory timeline.
Sources
- https://www.drugpatentwatch.com/